Skip to main content

Table 1 72 hr IC 50 for AI and adherent OS cells in the presence of doxorubicin or cisplatin

From: Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling

  

Doxorubicin

Cisplatin

Cell type

Mean IC50 (uM)

Fold change

Mean IC50 (uM)

Fold change

MS206-2

Adherent

0.062 ± 0.01

28.8^

4.38 ± 0.98

5.7^

AI

1.79 ± 0.4

25.2 ± 6.9

143B

Adherent

0.025 ± 0.01

13*

1.97 ± 0.19

1.9*

AI

0.31 ± 0.1

3.12 ± 0.10

mHOS

Adherent

0.085 ± 0.013

35*

3.10 ± 0.53

6.9*

AI

2.97 ± 1.9

21.4 ± 10.

MG-63

Adherent

0.13 ± 0.06

>75#

2.68 ± 1.6

6.2*

AI

>50% survival

16.9 ± 5.4

  1. ^Indicates p < 0.05 (two-tailed two-sample t-test).
  2. *Indicates p < 0.05 (wilcoxon signed-rank test).
  3. #Indicates >50% cell viability after treatment, so we could not calculate an IC50.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us